Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

• Status: Completed
• Trial end date: 2011-08-26
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Outpatient at least 12 years of age

• Both genders; females of childbearing potential must be willing to use birth control method

• Clinical diagnosis of asthma for ≥12 weeks

• Best pre-bronchodilator FEV1 of 40%-90% predicted

• Reversibility of FEV1 of at least 12% and 200mls

• Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit

• Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits

Exclusion Criteria:

• History of life-threatening asthma

• Respiratory infection within last 4 weeks leading to change in asthma management

• Asthma exacerbation within last 3 months

• Concurrent respiratory disease or other disease that would confound study participation or affect subject safety

• Allergies to study drugs, study drugs' excipients, or medications related to study drugs

• Taking another investigational medication or medication prohibited for use during the study.

• Previous participation in a vilanterol (GW642444) study